secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ainos, Inc. (AIMD)
CIK:        0001014763
Form:       8-K
Filed at:   2026-09-28T12:00:27+00:00
Accession:  0001493152-26-044454
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Ainos licenses VELDONA worldwide to BioPhoenix; $600K upfront, up to ~$10M in fees plus 25% sublicense revenue
--------------------------------------------------------------------------------

- Ainos granted BioPhoenix an exclusive, worldwide license to VELDONA for Sjögren's disease and thrombocytopenia; $600,000 upfront fee due within 15 business days after delivery conditions.
- BioPhoenix pays a one-time first-sublicense fee and 25% of applicable net sublicensing revenue; licensing all 15 additional indications would bring total fees to ~$10.0M.
- BioPhoenix funds and executes clinical/regulatory development, reducing Ainos' independent capital needs; Ainos retains platform ownership and prioritizes AI Nose/Chemical Intelligence.
- Ainos is barred from competing in the licensed indications worldwide during the term and for 10 years after; term runs to later of last patent expiry or 20 years post-9/24/2026.
- VELDONA history: 68 studies (3 Phase I, 63 Phase II, 2 Phase III), 16 indications, ~6,000 participants; Sjögren's had ~497 patients in two Phase III trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1014763/000149315226044454/0001493152-26-044454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1014763/000149315226044454/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-044454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer